Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492506 | 0.91 | HRH3 (0.52) | MAOBHRH3 | |
| SCHEMBL4505136 | 0.79 | HRH3 (0.48) | MAOBHRH3 | |
| SCHEMBL4506214 | 0.78 | HRH3 (0.55) | MAOBHRH3 | |
| SCHEMBL4496358 | 0.77 | HRH3 (0.72) | MAOBHRH3POLBMAPTKDM4E | |
| SCHEMBL267674 | 0.76 | MAOB (0.59) | MAOBHRH3POLBMAPTKDM4E | |
| SCHEMBL19584941 | 0.76 | MAOB (0.62) | MAOBHRH3POLBMAPTKDM4E | |
| SCHEMBL4498814 | 0.76 | MAOB (0.49) | MAOBHRH3HRH1POLBMAPT | |
| SCHEMBL4509193 | 0.75 | MAOB (0.48) | MAOBHRH3POLBMAPTKDM4E | |
| SCHEMBL4501879 | 0.75 | HRH3 (0.52) | MAOBHRH3 | |
| SCHEMBL4490641 | 0.74 | HRH3 (0.49) | MAOBHRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608617-B2 | Naphthaline derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1755593-B1 | NAPHTHALENE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | MCARTHUR SILVIA G | 2007-11-15 | — | — | US | disclosed |
| US-7259158-B2 | Naphthaline derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HOFFMAN-LA ROCHE INC. | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | MAOB 1735/4885HRH3 1/4885HRH1 3/4885 |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | MAOB 1735/4885HRH3 1/4885HRH1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.